Experts said Durvalumab could be a ‘game changer’.

Evening Standard

London

Greater London

England

United Kingdom

‘Increased survival rates’ for bladder cancer patients given immunotherapy drug

Ad Fontes Media

All Sides

Media Bias/Fact Check

The Independent

Evgeny Lebedev

Alfred Harmsworth (barrister)

Geraldine Mary Harmsworth

Patricia Harmsworth, Viscountess Rothermere

Carron Greig

Patients using the drug were more likely to still be alive two years after treatment

My London

Reach plc

A 'game-changer' study found advanced bladder cancer patients treated with the drug durvalumab were a third less likely to see the disease progress or return

Get Surrey

Surrey

New cancer drug could be 'game changer' for survival rates after UK trials

Bladder cancer patients given an immunotherapy drug are a third less likely to see disease come back and are more likely to survive, according to a “game-changer” study. Patients with advanced (muscle-invasive) bladder cancer had significantly less risk of cancer progressing or returning when treated with durvalumab, and were more likely to still be alive two years after treatment. Experts from the University of Sheffield and Barts Cancer Instit…

Jersey Evening Post

Claverley Group

Market Consensus Bankinter  Pfizer achieves positive results from a clinical trial with its candidate for treatment for bladder cancer. It is an advanced phase III trial of the sasanlimaben principle in combination with the vaccine containing tuberculosis Bacillus Calmette-Guérin, which has achieved primary safety and survival goals in patients with non-muscle invasive bladder cancer that have not been previously treated. This type of cancer acc…

Consenso del Mercado Bankinter | Pfizer consigue resultados positivos de un ensayo clínico con su candidato a tratamiento contra el cáncer de vejiga. Es un ensayo de fase III avanzado del principio sasanlimaben en combinación con la vacuna conta la tuberculosis Bacillus Calmette-Guérin, que ha logrado los objetivos primarios de seguridad y supervivencia en pacientes con cáncer de vejiga no muscular invasivo que no han sido tratados previamente. …

Noticias Bolsas internacionales Pfizer consigue resultados positivos en un ensayo clínico de su candidato contra el cáncer de vejiga

Consenso del Mercado

News International bags Pfizer gets positive results in a clinical trial of its candidate against bladder cancer

Patients with advanced bladder cancer who received an immunotherapy drug had a lower risk of disease recurrence while increasing their survival rates, a phase 3 clinical trial found. In a study of 1,063 patients with myoinfiltrative bladder cancer, it was found that durvalumab significantly reduced the risk of progression and recurrence of the disease. It also increases the chances of patients still being alive two years after diagnosis. Durvalu…

Οι ασθενείς με προχωρημένο καρκίνο της ουροδόχου κύστης που έλαβαν ένα ανοσοθεραπευτικό φάρμακο διέτρεχαν μικρότερο κίνδυνο υποτροπής της νόσου, ενώ παράλληλα αυξήθηκαν τα ποσοστά επιβίωσής τους, όπως διαπίστωσε κλινική δοκιμή φάσης 3. Σε μελέτη που συμμετείχαν 1.063 ασθενείς με μυοδιηθητικό καρκίνο της ουροδόχου κύστης, διαπιστώθηκε πως το φάρμακο δουρβαλουμάμπη (durvalumab) μειώνει σημαντικά τον κίνδυνο εξέλιξης και υποτροπής της νόσου. Αυξάνε…

Καρκίνος της ουροδόχου κύστης: Φάρμακο αυξάνει τα ποσοστά επιβίωσης των ασθενών

www.ertnews.gr

Bladder cancer: Drug increases patient survival rates

Your support helps us to tell the story 
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it’s investigating the financials of Elon Musk’s pro-Trump PAC or producing our latest documentary, ‘The A Word’, which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging. At such a critical …

elrisala.com

Experts said Durvalumab could be a ‘game changer’. Bladder cancer patients given an immunotherapy drug are a third less likely to see disease come back and are more likely to survive, according to a “game-changer” study. Patients with advanced (muscle-invasive) bladder cancer had significantly less risk of cancer progressing or returning when treated with durvalumab, and were more likely to still be alive two years after treatment. Experts from …

perspectivemedia.com

Sign up for our free Health Check email to receive exclusive analysis on the week in health Get our free Health Check email Get our free Health Check email Bladder cancer patients given an immunotherapy drug are a third less likely to see disease come back and are more likely to survive, according to a “game-changer” study. Patients with advanced (muscle-invasive) bladder cancer had significantly less risk of cancer progressing or returning when…

‘Increased survival rates’ for bladder cancer patients given immunotherapy drug

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics